Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Marker Therapeutics, Inc. (MRKR)

1.4614   -0.299 (-16.97%) 03-22 12:11
Open: 1.65 Pre. Close: 1.76
High: 1.73 Low: 1.45
Volume: 28,678 Market Cap: 12(M)

Technical analysis

as of: 2023-03-22 11:48:14 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.43     One year: 2.82
Support: Support1: 1.54    Support2: 1.28
Resistance: Resistance1: 2.08    Resistance2: 2.42
Pivot: 1.93
Moving Average: MA(5): 1.78     MA(20): 1.98
MA(100): 2.9     MA(250): 3.26
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 17.4     %D(3): 21.1
RSI: RSI(14): 25
52-week: High: 6.59  Low: 0.26
Average Vol(K): 3-Month: 42 (K)  10-Days: 35 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MRKR ] has closed below the lower bollinger band by 9.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MRKR ] is to continue within current trading range. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.76 - 1.77 1.77 - 1.78
Low: 1.65 - 1.66 1.66 - 1.67
Close: 1.74 - 1.76 1.76 - 1.78

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Headline News

Wed, 22 Mar 2023
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results - Yahoo Finance

Tue, 21 Mar 2023
JANONE INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers (form 8-K) -

Fri, 27 Jan 2023
Fate Therapeutics Inc (FATE) Stock Gains 4.94% This Week: Is It a Good Pick? - InvestorsObserver

Tue, 13 Dec 2022
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million - Yahoo Finance

Tue, 22 Nov 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601 ... - BioSpace

Thu, 10 Nov 2022
Marker Therapeutics Reports Q3 2022 Operating and Financial ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 9 (M)
Shares Float 7 (M)
% Held by Insiders 13.4 (%)
% Held by Institutions 24.6 (%)
Shares Short 49 (K)
Shares Short P.Month 59 (K)

Stock Financials

EPS -0.62
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.54
Profit Margin (%) 0
Operating Margin (%) -516.3
Return on Assets (ttm) -39.7
Return on Equity (ttm) -95.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -3.11
Sales Per Share 0.81
EBITDA (p.s.) -3.91
Qtrly Earnings Growth 0
Operating Cash Flow -26 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -2.58
PEG Ratio 0
Price to Book value 2.9
Price to Sales 1.92
Price to Cash Flow -0.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-09-15
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.